RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-03

Study Completion Date

2022-06-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, parallel-arm, randomized (1:1) multicenter trial to demonstrate that RECELL treatment of partial-thickness burn injuries, can safely and effectively increase the incidence of Day 10 healing compared with a standardized wound dressing.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

RES Prepared With RECELL® Compared to Conventional Care for Healing of Donor Sites in Ages 1-16 Years

NCT03624192

Skin; Deformity

TERMINATED NA

ReCell® Combined With Meshed Skin Graft in the Treatment of Acute Burn Injuries

NCT02380612

Burns

COMPLETED NA

A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries

NCT01138917

Burns

COMPLETED NA

Continued Access to the Recell® Device for Treatment of Acute Burn Injuries

NCT03333941

Burns

COMPLETED

RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction

NCT04091672

Full-thickness Skin Defects Degloving Injuries Crush Injuries +7 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Burns

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

1. Blinded Evaluator/Observer - local burn specialist
2. Independent Reviewer

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RECELL® Autologous Cell Harvesting Device

RECELL + Telfa™ Clear and Xeroform™ dressings

Conventional autografting (only when indicated)

Group Type EXPERIMENTAL

RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device

Intervention Type DEVICE

Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings.

Conventional autografting (only when indicated)

Intervention Type PROCEDURE

When indicated, conventional autografting in accordance with Investigator's standard practice

Mepilex® Ag Wound Dressing

Mepilex® Ag Wound Dressing

Conventional autografting (only when indicated)

Group Type ACTIVE_COMPARATOR

Mepilex® Ag Wound Dressing

Intervention Type COMBINATION_PRODUCT

Application of Mepilex® Ag Wound Dressing

Conventional autografting (only when indicated)

Intervention Type PROCEDURE

When indicated, conventional autografting in accordance with Investigator's standard practice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RES (Regenerative Epidermal Suspension) prepared using the RECELL® Autologous Cell Harvesting Device

Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings.

Intervention Type DEVICE

Mepilex® Ag Wound Dressing

Application of Mepilex® Ag Wound Dressing

Intervention Type COMBINATION_PRODUCT

Conventional autografting (only when indicated)

When indicated, conventional autografting in accordance with Investigator's standard practice

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patients aged 1 through 16 years (inclusive) with a partial-thickness thermal burn injury.
2. The patient has a thermal burn injury that is:

1. ≤ 30% TBSA (exclusive of superficial areas) and
2. ≤ 10% of the burn injury TBSA is a full-thickness burn.
3. The Index Burn must be a clean partial-thickness burn injury \> or = to 160 cm2 and between 2-20% BSA (inclusive).
4. The Index Burn may not cover the face, hand, foot or perineum/genitalia (Note: a patient with wounds in these areas may be enrolled but the Index Burn Area may not include these areas).
5. The patient and/or guardian agrees to comply with all compulsory study procedures and visit schedule.
6. The patient and/or parent/guardian agrees to abstain from any other treatment for closure of the Index Burn for the duration of the study, unless medically necessary.
7. The patient and/or parent/guardian agrees to abstain from enrollment in any other interventional clinical trial for the duration of the study.
8. In the opinion of the investigator, the patient and/or parent/guardian must be able to:

1. Understand the full nature and purpose of the study, including possible risks and adverse events,
2. Understand instruction, and
3. Provide voluntary informed written consent/assent as appropriate for study participation.

1. Patient randomized (and will be treated) within 72 hours from the time of the burn injury.

Exclusion Criteria

1. Not able to understand English or Spanish.
2. Burns caused by chemicals, electricity or radiation.
3. Patients presenting with only 3rd-degree/full-thickness wounds which require immediate autografting.
4. Burn injury has had prior treatment for definitive closure.
5. Patients for whom use of sedation/general anesthesia is not medically appropriate.
6. Superficial/trivial burns or burns that in the investigator's opinion appear to be healing sufficiently such that care under this protocol would be inappropriate.
7. Patient requires immediate or staged surgical procedures for closure of their partial-thickness burns.
8. Conditions, e.g., previous burn injury to study area, poor nutritional status, poorly controlled diabetes mellitus (HbA1c \>9%), that in the investigator's opinion may compromise subject safety or trial objectives.
9. Current use of medications, e.g., immunosuppressive agents (excluding inhaled corticosteroids), that in the investigator's opinion may compromise subject safety or trial objectives.
10. Inhalation injury.
11. Active infection, cellulitis or need for immediate grafting at the planned treatment areas.
12. Concerns for parent/guardian's ability to provide appropriate follow-up care.
13. Subjects with a known hypersensitivity to trypsin or compound sodium lactate for irrigation solution.
14. Subjects with a known sensitivity to silver.
15. In post-pubescent girls, pregnant or breast-feeding (pregnancy test should be performed in accordance with local institutional requirements).
16. Immediate life-threatening condition or life expectancy less than one year.
17. Previous randomization within this investigation.

Consented subjects who do not meet the post-randomization eligibility criteria and did not receive study treatment will be followed through the Day 28 visit and then withdrawn from the study. The criteria for which exclusion was based will be documented.

Minimum Eligible Age

1 Year

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No